PROF logo

PROFOUND MEDICAL CORP

PROFNASDAQ
๐Ÿ† #2777 by market capEarnings Nov 12US Equity
$6.98โ–ผ $0.34 (โˆ’4.90%)
๐ŸŒ™ After hours$6.98โ–ฒ 0.00%Regular close ยท extended-hours price shown
1hโ€”
24hโ–ผ 4.9%
7dโ–ผ 12.2%
14dโ–ผ 3.8%
30dโ–ผ 2.2%
1yโ–ฒ 24.2%
๐ŸฆMarket Cap
$254M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+61.1%
High Growth
๐Ÿ“ŠGross Margin
71.7%
High
๐Ÿ’ตFCF Margin
-188.7%
Thin
โš–๏ธP/S Ratio
13.4x
Elevated
Otter Score
59
Weak

Trading Snapshot

Day Range
$6.91 โ€“ $7.10
52-Week Range
$3.76 โ€“ $8.95
Volume
$3.82B
Avg Volume
$4.11B
Shares Outstanding
36.3M
Next Earnings
Sep 16, 2026

Fundamentals Snapshot

Annual Revenue
$16M
Last Q Revenue
$2M
P/E Ratio
-7.2
P/S Ratio
13.4x
EPS (TTM)
$-0.89
Dividend Yield
0.00%

Why Investors Own PROF

  • โœ“High-growth profile โ€” revenue up +30.9% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 77% gross margin and 8% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$16Mโ–ฒ +28.4% YoY
Gross Margin (TTM)
76.7%โ–ผ โˆ’0.1% YoY
Operating Income (TTM)
$2Mโ–ฒ +28.4% YoY
Free Cash Flow (TTM)
$1Mโ–ฒ +28.4% YoY

About PROFOUND MEDICAL CORP

Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids โ€“ including through non-invasive methods โ€“ and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
59/100

Analyst Ratings

โ“˜
Consensus
Buy
5 analysts
Strong Buy1
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates